Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 19, 2019Plan to Initiate PROTECT Study for PRV-031 (teplizumab) in T1D Patients in Q2
-
Mar 11, 2019* Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis
-
Feb 27, 2019* Soliqua 100/33 now approved as an add-on to diet and exercise for adults with type 2 diabetes
-
Feb 25, 2019Praluent® (alirocumab) continues to be available in the U.S.
-
Feb 11, 2019* This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients
